Top Azithromycin Brands for Reliable Healthcare Choices

Azithromycin, a widely-used antibiotic, has several reputable brands that are trusted by healthcare professionals and consumers alike. These brands are known for their commitment to quality and safety, ensuring the medication's efficacy in treating bacterial infections. Factors such as bioavailability, manufacturing standards, and patient reviews often guide the selection of these preferred brands. For a comprehensive look at the top azithromycin brands available today, continue reading below.

Illustration of azithromycin

Best brands of azithromycin in 2025

Zithromax

Zithromax, a brand of azithromycin produced by Pfizer, is a leading macrolide antibacterial drug renowned for its effectiveness in treating mild to moderate infections caused by susceptible bacteria. It is distinguished by its rapid and extensive penetration into intracellular and interstitial tissue compartments, along with prolonged tissue and serum half-lives. Azithromycin, under the Zithromax brand, has seen significant demand, particularly in treating respiratory infections, with the global azithromycin market projected to grow at a CAGR of 5.5% from 2025 to 2032, reaching USD 11.92 billion by 2032. The drug is available in various forms, including oral tablets and suspension, and is recommended for a single dose of 1 g for certain infections like chlamydia. Its short-duration, high-compliance, and cost-effective regimens have improved treatment outcomes. For more information about Zithromax and its usage, visit the official Pfizer website.

Azax

Azax, a brand by Cipla, is renowned for its high-quality azithromycin formulations, which have garnered trust globally for their efficacy and safety. Azithromycin, a macrolide antibiotic, is effective in treating a wide range of bacterial infections and has additional benefits in reducing inflammation in conditions like asthma and chronic obstructive pulmonary disease. With an elimination half-life of approximately 68 hours, Azax's azithromycin ensures sustained bacteriostatic levels in the body. The drug's bioavailability is around 38% for 250 mg capsules, and it is well-absorbed, especially when taken on an empty stomach. Cipla's stringent manufacturing standards and compliance with regulatory requirements make Azax a reliable choice.

Azithral

Azithral, a brand of azithromycin produced by Alembic Pharmaceuticals, is a leading player in the global azithromycin market, renowned for its high-quality and effective treatment of bacterial infections. In January 2020, Alembic Pharmaceuticals received FDA approval for its generic Azithromycin tablets, marking a significant step in providing crucial treatment options during the COVID-19 pandemic. The market for azithromycin is projected to grow at a CAGR of 5.5% from 2025 to 2032, with the global market size expected to reach USD 11.92 billion by 2032. Azithral's oral, injectable, and ophthalmic formulations address various medical needs, contributing to the dominance of the oral segment in the market. The brand's strong presence in regions like North America and Asia-Pacific further solidifies its market position. For more information about Azithral's formulations, visit the product page on Cheap Medicine Shop.

Zimax

Zmax, a product of Abbott, is a highly regarded formulation of azithromycin, known for its extended-release microspheres for oral suspension. This single-dose formulation contains 2 g of azithromycin dihydrate, making it effective for treating mild to moderate infections such as acute bacterial sinusitis and community-acquired pneumonia. The bioavailability of azithromycin in Zmax is notable, with a bioavailability of 38% for oral capsules, and its elimination half-life is approximately 68 hours. The market demand for azithromycin, including Zmax, has surged, particularly during the COVID-19 pandemic, with the global azithromycin market projected to grow at a CAGR of 5.5% by 2032. Zmax's unique formulation ensures high concentrations of azithromycin in mononuclear and polymorphonuclear leukocytes, enhancing its therapeutic efficacy. For detailed information on Zmax, visit the Zmax drug page.

Azicip

Azicip 500 Tablet, produced by Cipla, is a highly effective azithromycin-based antibiotic used to treat various bacterial infections, including those of the respiratory system, skin, throat, and urinary tract. It works by preventing bacterial protein synthesis, making it a preferred choice for patients intolerant to penicillin. With a bioavailability of 38% for oral administration and an elimination half-life of 68 hours, Azicip 500 ensures sustained bacteriostatic levels in infected tissues. Available in strips of 5 tablets, it is priced competitively, offering a 15% discount on the MRP of Rs79.16. This medication is well-tolerated and has fewer drug-drug interactions compared to other macrolide antibiotics. For more details, you can visit their official online order page.

Zitromax

Zithromax, a brand of azithromycin produced by Wockhardt, is a leading player in the global azithromycin market, which is projected to grow from USD 7.01 billion in 2023 to USD 10.33 billion by 2030 at a CAGR of 5.68%. The drug's widespread use in treating bacterial infections, particularly respiratory infections, has driven its demand. Technological advancements in manufacturing, such as the use of continuous flow reactors, have improved the production efficiency and purity of azithromycin. The Asia-Pacific region, particularly China, is expected to dominate the market due to its robust healthcare infrastructure and large population. Zithromax's efficacy and patient compliance have been enhanced by innovations in drug delivery systems, including controlled-release formulations. For more information, visit Zithromax Drug Information.

Sumamed

Sumamed, a brand of azithromycin produced by Teva Pharmaceuticals, is renowned for its high quality and efficacy. Azithromycin, the active ingredient, boasts a bioavailability of approximately 34-52% following oral administration, and it is widely distributed in tissues with a volume of distribution of 31.1 L/kg. Introduced after the synthesis involving the modification of erythromycin A, azithromycin has become a cornerstone in treating various bacterial infections since its patent application in the late 20th century. It is particularly noted for its long serum half-life of 68 hours and its biliary excretion, with about 6% of the dose excreted unchanged in urine over a week. This antibiotic is available in various strengths, including 500mg and 250mg oral doses, and is used to treat a range of infections, including acute bacterial sinusitis and community-acquired pneumonia. For further details, explore more about Sumamed at Pharmacompass.

Aziboost

Azithromycin, particularly under the brand Aziboost by Macleods Pharmaceuticals, is renowned for its high quality and efficacy in treating a variety of bacterial infections. With a bioavailability of 37% following oral administration, Aziboost ensures effective absorption and distribution of the antibiotic, concentrating significantly in tissues such as the lung, tonsils, and prostate. Its long terminal elimination half-life of 68 hours allows for convenient dosing regimens. Aziboost is also notable for its minimal impact on CYP3A4, reducing the risk of drug-drug interactions compared to other macrolides. This makes it a safer option for patients, especially those with cardiovascular risks or those taking other medications.

Aziwin

Aziwin, a product of Eris Lifesciences, is renowned for its high-quality azithromycin formulations, which are highly effective in treating a wide range of bacterial infections, including respiratory, skin, and sexually transmitted infections. With a bioavailability of approximately 37% from a single oral dose of 500 mg, Aziwin ensures peak serum concentrations that are sufficient to combat relevant pathogens. The drug's ability to achieve tissue concentrations exceeding 3 mg/kg in various tissues makes it particularly effective against infections such as bronchitis, pneumonia, and chlamydia. Aziwin 250 mg tablets are well-tolerated and preferred for their ease of administration, often prescribed as a single-dose therapy for certain infections. The global demand for azithromycin, driven by its broad-spectrum activity, is expected to grow at a CAGR of 5.5% to 5.68% by 2030, further solidifying Aziwin's position in the market. For more information on Aziwin 250 mg tablets, visit Apollo Pharmacy's website.

Ausun

Sun Pharmaceutical, under its brand, is a leading producer of azithromycin, leveraging its extensive manufacturing network of 43 sites worldwide, including 29 finished dosage and 14 API manufacturing facilities. This global presence enables the company to service markets effectively, ensuring high product availability. Sun Pharma's strategy includes participating in public sector tenders and employing competitor-based pricing, which has helped in expanding access to azithromycin in various countries, including Kenya and other emerging markets. The company's large manufacturing capacity and flexible operations contribute to its strong market position. By 2023, Sun Pharma reported significant revenues from its global operations, highlighting its robust presence in the pharmaceutical sector. For more detailed insights, refer to Sun Pharma's report on their global operations.